dr. tykodi on the keynote-427 trial with pembrolizumab in rcc
Published 3 years ago • 217 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
1:16
dr. tykodi on the clinical implications of the keynote-427 trial in advanced rcc
-
0:59
dr. tykodi on the efficacy of dual checkpoint blockade in rcc
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
4:10
non-clear cell kidney cancer trial updates: calypso and keynote-427
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
4:20
trial updates in mrcc from asco: keynote-427, resort, e2810 & immotion151
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
2:31
recent immunotherapy advances in rcc
-
1:17
dr. zhang discusses the keynote-564 trial in rcc
-
1:08
clinical trials in adjuvant rcc
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
0:35
the latest developments in adjuvant therapy for rcc
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale